Lucid Diagnostics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
360 Madison Ave Fl 25, New York City, Ne...Phone Number
(888) 582-4339Website
www.luciddx.comRevenue
<$5 MillionStock Symbol
LUCDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.Explore more
Lucid Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lucid Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Lucid Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Lucid Diagnostics has new funding data
Product Launch: Get notified when Lucid Diagnostics launches new products
Congratulate Masked Content for being promoted to Masked Content at Lucid Diagnostics
Website visits: Recent activity has been detected on your website
Check out if Lucid Diagnostics is spiking on competitors!
Earning: See what the market has to say on Lucid Diagnostics recently announced quarterly report
Click to see if Lucid Diagnostics had a recent Job posting/layoffs
Check if Lucid Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Lucid Diagnostics
Find 3 more new buyers
Compare Similar Companies to Lucid Diagnostics
Compare insights from companies similar to Lucid Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$40.1M
51-200
Private
-
2008
MM
Mariam MaghribiShifamed Chief Business Officer & President & CEO, Atia Vision & Tioga Cardiovascular
Company Profile Activity
Activity Insights
Lucid Diagnostics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lucid Diagnostics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lucid Diagnostics.
Lucid Diagnostics financials insights
Gather financial insights about Lucid Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$70M
2025
Stock Offering
$15.3M
Lucid Diagnostics Tech Stack
A closer look at the technologies used by Lucid Diagnostics
Most Recent Scoops
Event
Product Marketing, Events, Training, Sales, Software, Safety, First Responder, Field Marketing, Operations
Open Position
Project
Lucid Diagnostics has reported that its Lucid clinical team provides mobile EsoGuard testing services, facilitating the test's integration into various medical practices, including Dr. Panzarella's in Florida where a mobile van conducts monthly patient testing.
Medical Research, Healthcare Operations, Healthcare Technology
Project
Lucid Diagnostics has reported that its EsoGuard has been described as a "no-brainer" and "best practice" with a high benefit-to-risk ratio by Dr. Michael Smith, Associate Assistant Chief of Gastroenterology at Mount Sinai and incoming President of the American Foregut Society.
Doctors / Physicians, Medical Research, Healthcare Technology
Project
Business Intelligence, Analytics & Insights, Medical Research, Healthcare Technology
Lucid Diagnostics News & Media
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones PAVmed advanced its...Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sysLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May 14, at 8:30 AM EDT NEW YORK, May...Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lucid Diagnostics
Sign Up For FreeTo access detailed company insights
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal... Read More
